Stanford Develops Experimental Nasal Spray Aiming to Protect Against Multiple Respiratory Infections

ଓଡିଶା

ଲଗାଣ ବର୍ଷାରେ ବାଲେଶ୍ୱରରେ ନଷ୍ଟ ହେଲା ଧାନ ବିହନ; ସରକାରୀ...

July 22, 2026

ସିଜେପି ଆନ୍ଦୋଳନକୁ ନବୀନଙ୍କ ସମର୍ଥନକୁ ନେଇ ବର୍ଷିଲେ ଭର୍ତ୍ତୃହରି ମହତାବ;...

July 22, 2026

ବାହୁଡ଼ା ଯାତ୍ରା ପାଇଁ ସରକାର ସତର୍କ; ଗାଇଡ୍‌ଲାଇନ୍ ମାନିବାକୁ ଶ୍ରଦ୍ଧାଳୁଙ୍କୁ...

July 22, 2026

ସମୟ ସରିଲା, ଥାନାରେ ହାଜର ହେଲେନି IAS ରାଜେଶ ବର୍ମା;...

July 22, 2026

ଖେଳ

୨୦୨୭ ବିଶ୍ୱକପ୍ ଲକ୍ଷ୍ୟରେ ରୋହିତ-ବିରାଟ; ଦିନିକିଆ କ୍ରିକେଟ୍‌ରେ ହେବ ଅଗ୍ନିପରୀକ୍ଷା

July 22, 2026

ବୈଭବ ସୂର୍ଯ୍ୟବଂଶୀଙ୍କୁ ନେଇ ସିକନ୍ଦର ରଜାଙ୍କ ବଡ଼ ବୟାନ; ‘ଏବେ...

July 21, 2026

୨୦୨୭ ୱାନଡେ ବିଶ୍ୱକପ୍‌ରୁ ରୋହିତ-କୋହଲିଙ୍କୁ ବାଦ ଦେବା ସହଜ ନୁହେଁ:...

July 21, 2026

ବିଶ୍ୱକପ୍ ଫାଇନାଲ୍ ପରାଜୟର ଯନ୍ତ୍ରଣା ଭୁଲିପାରୁନାହାନ୍ତି ମେସି, କହିଲେ- ‘ଏହି...

July 21, 2026

Stanford Develops Experimental Nasal Spray Aiming to Protect Against Multiple Respiratory Infections

Researchers at Stanford University are testing a nasal spray that may offer broad protection against viruses, bacteria, and even allergies. Human trials are needed to confirm its safety and effectiveness.

Published by Somesh | February 20, 2026

Stanford University researchers in the US are developing an experimental nasal spray designed to provide wide-ranging protection against respiratory illnesses, including common colds, flu, and dangerous bacterial infections. Unlike traditional vaccines, which target a specific pathogen, this “universal vaccine” primes the lungs’ immune cells to respond rapidly to almost any invading virus or bacterium. Animal studies have shown that the spray boosts lung macrophages, putting them on “amber alert,” and reduces viral infections by 100–1,000 times over three months. It also showed promise against antibiotic-resistant bacteria likeStaphylococcus aureusandAcinetobacter baumannii.

Experts caution that these results are preliminary, as human immune systems differ from mice, and keeping immune cells constantly alert carries potential risks of inflammation or tissue damage. Clinical trials are being planned to test both safety and effectiveness in humans. Researchers envision the spray as a complement to conventional vaccines rather than a replacement, potentially offering protection at the start of pandemic outbreaks or seasonal respiratory surges.

If human trials are successful, the once-a-season nasal spray could revolutionise respiratory disease prevention, providing temporary but broad protection to millions while pathogen-specific vaccines are developed. For now, the approach remains experimental, but it represents a dramatic shift in vaccine science and could pave the way for a new era of universal respiratory protection.